Added to YB: 2026-01-06
Pitch date: 2026-01-02
TEVA [neutral]
Teva Pharmaceutical Industries Limited
+4.04%
current return
Author Info
Kontra Investment Xchange is trying to build wealth by investing in good companies and letting those investments compound over many years. Sign up for the newsletter.
Company Info
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
Market Cap
$35.5B
Pitch Price
$99.10
Price Target
40.00 (-61%)
Dividend
N/A
EV/EBITDA
10.63
P/E
50.15
EV/Sales
3.00
Sector
Pharmaceuticals
Category
turnaround
Teva Pharmaceuticals: The pivot to Specialty Pharma is in full swing
TEVA (update): Transforming from generics to specialty pharma; branded revenue to grow from 17% (2025) to 35%+ (2030) led by Austedo >$3B sales; 10% EPS/EBITDA CAGR; debt falling from $16B to $9.4B by 2028; IRA risk removed; UBS/Piper $37-40 targets as market re-rates from 6-8x generics multiple to biopharma peer valuation.
Read full article (3 min)